Fighting Cancer

Every Step of the Way

Vigilant Biosciences is transforming the early detection and intervention of cancer.

Learn More
Media Kit

Dedicated to Early Intervention. And Life.

Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. Its OncAlert™ Oral Cancer Risk Assessment System uses patented technology that is highly-accurate and specific.

Learn More
Did You Know?

When diagnosed early, oral cancer patients have an 80 to 90% survival rate.

Unfortunately, over 40% of those diagnosed with oral cancer will die within five years due to these cases being discovered as a late stage malignancy.

Learn More

At A Glance

Transforming Early Detection

Vigilant Biosciences’ products are based on patented technology that detects specific protein markers known to clinically show elevated risk for early stage cancers, even prior to observation of visual or physical symptoms... more

Easy-to-Use and Non-Invasive

OncAlert™ products utilize a simple oral rinse procedure that is easy to administer and non-invasive for the patient... more

Accurate and Objective Results at the Point-of-Care or Lab

Both the rapid point-of-care test and the lab assay that comprise the OncAlert™ system provide a timely, accurate, and specific risk assessment for oral cancer... more


News + Press

  • mlo_logo

    Special Feature: Saliva as a diagnostic tool

    By Elizabeth Franzmann, MD, July 2015 Salivary diagnostics holds tremendous potential for the diagnosis, prognosis, and monitoring of cancer.1 The specimen can be obtained simply, inexpensively, and less invasively than blood and thus can be collected without special training.1-3 Saliva…more

  • vb-400x210

    Vigilant Biosciences, Inc. Expands Board of Directors with Esteemed Dental Professional Dr. Linda Niessen

    FORT LAUDERDALE, Fla. – Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, announced today the expansion of its Board of Directors with the addition of Linda Niessen, D.M.D.,…more

  • dentistryIQ

    Vigilant Biosciences enters exclusive agreement with Eurobio for distribution of OncAlert in France, Algeria, Morocco, and Tunisia; Interview with CEO Matthew Kim

    In what has already been a busy year for Vigilant Biosciences, the Ft. Lauderdale-based maker of early cancer detection products has reached another distribution deal. The company announced last week a three-year sales agreement with Eurobio (Les Ulis, France). Under…more

  • sunsentinel

    Vigilant Biosciences signs marketing partner for cancer-detection system

    Vigilant Biosciences, a Fort Lauderdale business that develops systems for early detection of cancer, has signed an exclusive sales and marketing partnership with Eurobio. The company will distribute Vigilant’s OncAlert Oral Cancer Risk Assessment System and the and the OncAlert…more

©2011-2015 Vigilant Biosciences, Inc. All Rights Reserved.